EE04282B1 - Pürasoolpürimidiinid, nende valmistamine ja kasutamine ravimina ning neid sisaldav kompositsioon - Google Patents

Pürasoolpürimidiinid, nende valmistamine ja kasutamine ravimina ning neid sisaldav kompositsioon

Info

Publication number: EE04282B1
Authority: EE; Estonia
Prior art keywords: pharmaceutical; preparation; composition containing; pyrimidines; pyrazole
Prior art date: 1996-02-07

Application number

EE9800124A

Other languages

English (en)

Estonian (et)

Other versions

EE9800124A (et

Inventor

R. Webb Thomas

R. Mccarthy James

J. Moran Terence

M. Wilcoxen Keith

Chen Chen

Huang Charles

Original Assignee

Janssen Pharmaceutica N.V.

Neurocrine Biosciences Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-07

Filing date

1997-01-30

Publication date

2004-04-15

1997-01-30 Application filed by Janssen Pharmaceutica N.V., Neurocrine Biosciences Inc. filed Critical Janssen Pharmaceutica N.V.

1998-10-15 Publication of EE9800124A publication Critical patent/EE9800124A/xx

2004-04-15 Publication of EE04282B1 publication Critical patent/EE04282B1/xx

Links

KEUDMLLLHGLIGH-UHFFFAOYSA-N 1h-pyrazole;pyrimidine Chemical class C=1C=NNC=1.C1=CN=CN=C1 KEUDMLLLHGLIGH-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Cardiology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

EE9800124A 1996-02-07 1997-01-30 Pürasoolpürimidiinid, nende valmistamine ja kasutamine ravimina ning neid sisaldav kompositsioon EE04282B1 (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1127996P	1996-02-07	1996-02-07
US2768896P	1996-10-08	1996-10-08
PCT/EP1997/000459 WO1997029109A1 (fr)	1996-02-07	1997-01-30	Pyrazolopyrimidines en tant qu'antagonistes du recepteur de crf

Publications (2)

Publication Number	Publication Date
EE9800124A EE9800124A (et)	1998-10-15
EE04282B1 true EE04282B1 (et)	2004-04-15

Family

ID=26682204

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9800124A EE04282B1 (et)	1996-02-07	1997-01-30	Pürasoolpürimidiinid, nende valmistamine ja kasutamine ravimina ning neid sisaldav kompositsioon

Country Status (27)

Country	Link
EP (1)	EP0880523B1 (fr)
JP (2)	JP3356291B2 (fr)
KR (1)	KR100421626B1 (fr)
CN (1)	CN1090189C (fr)
AR (1)	AR008577A1 (fr)
AT (1)	ATE336495T1 (fr)
AU (1)	AU713673B2 (fr)
BG (1)	BG102349A (fr)
BR (1)	BR9707391A (fr)
CA (1)	CA2233285C (fr)
CZ (1)	CZ244598A3 (fr)
DE (2)	DE880523T1 (fr)
DK (1)	DK0880523T3 (fr)
EA (1)	EA000803B1 (fr)
EE (1)	EE04282B1 (fr)
ES (1)	ES2168237T3 (fr)
HU (1)	HUP9900575A3 (fr)
ID (1)	ID15905A (fr)
IL (1)	IL123835A0 (fr)
NO (1)	NO310292B1 (fr)
NZ (1)	NZ330119A (fr)
PL (1)	PL191271B1 (fr)
PT (1)	PT880523E (fr)
SK (1)	SK106398A3 (fr)
TR (1)	TR199800792T2 (fr)
TW (1)	TW449599B (fr)
WO (1)	WO1997029109A1 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6124289A (en) *	1996-07-24	2000-09-26	Dupont Pharmaceuticals Co.	Azolo triazines and pyrimidines
AU747708B2 (en) *	1996-07-24	2002-05-23	Du Pont Pharmaceuticals Company	Azolo triazines and pyrimidines
US6313124B1 (en)	1997-07-23	2001-11-06	Dupont Pharmaceuticals Company	Tetrazine bicyclic compounds
US6191131B1 (en)	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
US6060478A (en) *	1996-07-24	2000-05-09	Dupont Pharmaceuticals	Azolo triazines and pyrimidines
US7094782B1 (en)	1996-07-24	2006-08-22	Bristol-Myers Squibb Company	Azolo triazines and pyrimidines
DK0920429T3 (da)	1996-08-06	2003-05-12	Pfizer	Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
US5723608A (en) *	1996-12-31	1998-03-03	Neurogen Corporation	3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
JP2001511813A (ja)	1997-02-18	2001-08-14	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法
US6235741B1 (en) *	1997-05-30	2001-05-22	Merck & Co., Inc.	Angiogenesis inhibitors
CA2291709A1 (fr) *	1997-05-30	1998-12-03	Merck & Co., Inc.	Nouveaux inhibiteurs d'angiogenese
NL1010018C2 (nl)	1997-09-09	1999-03-10	Duphar Int Res	Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6380203B1 (en)	1998-01-14	2002-04-30	Merck & Co., Inc.	Angiogenesis inhibitors
IL137019A0 (en) *	1998-01-28	2001-06-14	Du Pont Pharm Co	Azolo triazines and pyrimidines
WO1999045007A1 (fr) *	1998-03-06	1999-09-10	Janssen Pharmaceutica N.V.	Pyrazolo[4,3-b]pyridines antagonistes du facteur de liberation de la corticotropine (crf)
EP1068205A1 (fr)	1998-04-02	2001-01-17	Neurogen Corporation	Derives de 5,6,7,8-tetrahydro-9h pyrimidino 2,3-b]indole et de 5,6,7,8-tetrahydro-9h-pyrimidino 4,5-b]indole a substitution aminoalkyl: des ligands specifiques du crf1
US6472402B1 (en)	1998-04-02	2002-10-29	Neurogen Corporation	Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
AU2321000A (en) *	1999-01-29	2000-08-18	Sumitomo Chemical Company, Limited	Fat accumulation inhibitory agents
AU4331500A (en)	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolotriazines as crf antagonists
AU4203500A (en)	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
US6432989B1 (en)	1999-08-27	2002-08-13	Pfizer Inc	Use of CRF antagonists to treat circadian rhythm disorders
PL354675A1 (en)	1999-09-30	2004-02-09	Neurogen Corporation	Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
IL139197A0 (en)	1999-10-29	2001-11-25	Pfizer Prod Inc	Use of corticotropin releasing factor antagonists and related compositions
TWI271406B (en)	1999-12-13	2007-01-21	Eisai Co Ltd	Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
KR20030016222A (ko) *	2000-02-14	2003-02-26	니뽄 다바코 산교 가부시키가이샤	수술후 스트레스 예방ㆍ치료제
US6888004B2 (en)	2001-01-26	2005-05-03	Bristol-Myers Squibb Company	Imidazolyl derivatives as corticotropin releasing factor inhibitors
TWI312347B (en)	2001-02-08	2009-07-21	Eisai R&D Man Co Ltd	Bicyclic nitrogen-containing condensed ring compounds
BR0209252A (pt)	2001-04-27	2004-07-20	Eisai Co Ltd	Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas
US6872827B2 (en)	2002-04-26	2005-03-29	Chembridge Research Laboratories, Inc.	Somatostatin analogue compounds
US7161003B1 (en) *	2002-09-04	2007-01-09	Schering Corporation	Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7176216B2 (en)	2002-10-22	2007-02-13	Eisai Co., Ltd.	7-phenylpyrazolopyridine compounds
AU2003275589B2 (en)	2002-10-22	2009-05-28	Eisai R & D Management Co., Ltd.	7-phenyl pyrazolopyridine compounds
RS20050532A (sr)	2003-01-14	2007-12-31	Arena Pharmaceuticals Inc.,	Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
WO2004087707A1 (fr) *	2003-03-31	2004-10-14	Vernalis (Cambridge) Limited	Composes pyrazolopyrimidines et leur utilisation en medecine
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
KR20060056944A (ko)	2003-07-14	2006-05-25	아레나 파마슈티칼스, 인크.	대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
US7329662B2 (en) *	2003-10-03	2008-02-12	Hoffmann-La Roche Inc.	Pyrazolo-pyridine
US20070293511A1 (en) *	2003-12-22	2007-12-20	Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation	Crf Receptor Antagonists and Methods
JP4926720B2 (ja) *	2003-12-22	2012-05-09	スミスクラインビーチャム（コーク）リミテッド	Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
JP2008503444A (ja) *	2004-02-13	2008-02-07	エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド	Ｃｒｆ受容体アンタゴニスト、その調製法、その医薬組成物およびその使用
GB0519957D0 (en)	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
ATE512966T1 (de)	2005-02-11	2011-07-15	Hoffmann La Roche	Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
CN101142217B (zh) *	2005-03-21	2010-12-08	伊莱利利公司	咪唑并哒嗪化合物
PT1863818E (pt)	2005-03-23	2010-04-09	Hoffmann La Roche	Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
US7557103B2 (en)	2005-04-05	2009-07-07	Eli Lilly And Company	Imidazopyridazine compounds
EP1922321A1 (fr) *	2005-08-09	2008-05-21	Eirx Therapeutics Ltd	Composes de pyrazoloý1,5-a¨pyrimidine et leurs compositions pharmaceutiques
ATE463495T1 (de)	2005-09-27	2010-04-15	Hoffmann La Roche	Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
KR101088239B1 (ko)	2006-09-20	2011-11-30	일라이 릴리 앤드 캄파니	Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
MX2009003098A (es)	2006-09-20	2009-04-01	Lilly Co Eli	Compuestos de tiofen pirazolopirimidina.
KR101150581B1 (ko)	2007-07-26	2012-06-11	노파르티스 아게	유기 화합물
MY152687A (en)	2008-04-15	2014-10-31	Eisai R&D Man Co Ltd	3-phenylpyrazolo[5,1-b]thiazole compound
AR078521A1 (es)	2009-10-08	2011-11-16	Eisai R&D Man Co Ltd	Compuesto pirazolotiazol
CN103221410B (zh)	2010-09-22	2017-09-15	艾尼纳制药公司	Gpr119受体调节剂和对与其相关的障碍的治疗
GB201210686D0 (en)	2012-06-15	2012-08-01	Holsboermaschmeyer Neurochemie Gmbh	V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en)	2013-06-17	2013-07-31	Max Planck Innovation Gmbh	Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
CA3002540C (fr)	2015-01-06	2023-11-07	Arena Pharmaceuticals, Inc.	Utilisation de (r)-2-(7-(4-cyclopentyl-3(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acide acetique pour le traitement de conditions liees au recepteur s1p1
PL236355B1 (pl) *	2015-04-02	2021-01-11	Celon Pharma Spolka Akcyjna	Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
JP6838744B2 (ja)	2015-06-22	2021-03-03	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
IL311645B2 (en)	2016-07-12	2025-11-01	Revolution Medicines Inc	2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
CA3051054A1 (fr)	2017-01-23	2018-07-26	Revolution Medicines, Inc.	Composes de pyridine utilises en tant qu'inhibiteurs allosteriques de shp2
CN110446709B (zh)	2017-01-23	2023-09-12	锐新医药公司	作为变构shp2抑制剂的二环化合物
BR112020002967A2 (pt)	2017-08-14	2020-08-11	Spruce Biosciences, Inc.	antagonistas de receptor de fator de liberação de corticotropina
TWI803504B (zh) *	2017-08-14	2023-06-01	美商雲杉生物科技股份有限公司	促皮質素釋放因子受體拮抗劑
TWI852912B (zh)	2017-09-07	2024-08-21	美商銳新醫藥公司	Shp2抑制劑組合物以及治療癌症的方法
BR112020007058A2 (pt)	2017-10-12	2020-10-06	Revolution Medicines, Inc.	compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112020009757A2 (pt)	2017-12-15	2020-11-03	Revolution Medicines, Inc.	compostos policíclicos como inibidores alostéricos de shp2
MX2020011344A (es)	2018-04-27	2021-02-09	Spruce Biosciences Inc	Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
JP7397011B2 (ja)	2018-06-06	2023-12-12	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１ｐ１受容体に関連する状態を治療する方法
JP2023537598A (ja)	2020-08-12	2023-09-04	スプルースバイオサイエンシーズ，インク．	多嚢胞性卵巣症候群を処置するための方法および組成物
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4211753Y1 (fr) *	1964-06-06	1967-06-30
JPS6157587A (ja) *	1984-08-29	1986-03-24	Shionogi & Co Ltd	縮合複素環誘導体および抗潰瘍剤
JPH0211753A (ja) *	1988-06-29	1990-01-16	Raimuzu:Kk	ＴｉＡｌ系複合部材及びその製造方法
TW370529B (en) *	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines

1997
- 1997-01-30 ES ES97902295T patent/ES2168237T3/es not_active Expired - Lifetime
- 1997-01-30 KR KR10-1998-0703401A patent/KR100421626B1/ko not_active Expired - Fee Related
- 1997-01-30 JP JP52812397A patent/JP3356291B2/ja not_active Expired - Fee Related
- 1997-01-30 EE EE9800124A patent/EE04282B1/xx not_active IP Right Cessation
- 1997-01-30 DK DK97902295T patent/DK0880523T3/da active
- 1997-01-30 EP EP97902295A patent/EP0880523B1/fr not_active Expired - Lifetime
- 1997-01-30 CA CA002233285A patent/CA2233285C/fr not_active Expired - Fee Related
- 1997-01-30 WO PCT/EP1997/000459 patent/WO1997029109A1/fr not_active Ceased
- 1997-01-30 TR TR1998/00792T patent/TR199800792T2/xx unknown
- 1997-01-30 SK SK1063-98A patent/SK106398A3/sk unknown
- 1997-01-30 CN CN97191382A patent/CN1090189C/zh not_active Expired - Fee Related
- 1997-01-30 CZ CZ982445A patent/CZ244598A3/cs unknown
- 1997-01-30 DE DE0880523T patent/DE880523T1/de active Pending
- 1997-01-30 AT AT97902295T patent/ATE336495T1/de active
- 1997-01-30 AU AU15991/97A patent/AU713673B2/en not_active Ceased
- 1997-01-30 BR BR9707391A patent/BR9707391A/pt not_active Application Discontinuation
- 1997-01-30 IL IL12383597A patent/IL123835A0/xx active IP Right Grant
- 1997-01-30 DE DE69736513T patent/DE69736513T2/de not_active Expired - Lifetime
- 1997-01-30 HU HU9900575A patent/HUP9900575A3/hu unknown
- 1997-01-30 NZ NZ330119A patent/NZ330119A/en not_active IP Right Cessation
- 1997-01-30 PT PT97902295T patent/PT880523E/pt unknown
- 1997-01-30 EA EA199800394A patent/EA000803B1/ru not_active IP Right Cessation
- 1997-01-30 PL PL327284A patent/PL191271B1/pl not_active IP Right Cessation
- 1997-02-05 TW TW086101373A patent/TW449599B/zh not_active IP Right Cessation
- 1997-02-06 AR ARP970100473A patent/AR008577A1/es not_active Application Discontinuation
- 1997-02-07 ID IDP970392A patent/ID15905A/id unknown
1998
- 1998-03-25 NO NO19981357A patent/NO310292B1/no not_active IP Right Cessation
- 1998-03-25 BG BG102349A patent/BG102349A/xx unknown
2001
- 2001-09-03 JP JP2001265611A patent/JP2002121194A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
ATE336495T1 (de)	2006-09-15
EE9800124A (et)	1998-10-15
DE880523T1 (de)	2002-07-04
JP2002121194A (ja)	2002-04-23
IL123835A0 (en)	1998-10-30
EA199800394A1 (ru)	1998-10-29
BR9707391A (pt)	1999-07-20
DK0880523T3 (da)	2007-03-26
KR100421626B1 (ko)	2004-05-20
ES2168237T1 (es)	2002-06-16
CZ244598A3 (cs)	1998-10-14
AU713673B2 (en)	1999-12-09
SK106398A3 (en)	1998-12-02
HUP9900575A2 (hu)	1999-06-28
EP0880523B1 (fr)	2006-08-16
TR199800792T2 (xx)	1998-07-21
CA2233285C (fr)	2006-07-04
PT880523E (pt)	2007-01-31
AR008577A1 (es)	2000-02-09
NZ330119A (en)	2000-02-28
DE69736513T2 (de)	2007-04-05
TW449599B (en)	2001-08-11
KR19990067391A (ko)	1999-08-16
EA000803B1 (ru)	2000-04-24
EP0880523A1 (fr)	1998-12-02
JP2000503661A (ja)	2000-03-28
CA2233285A1 (fr)	1997-08-14
JP3356291B2 (ja)	2002-12-16
AU1599197A (en)	1997-08-28
ID15905A (id)	1997-08-14
BG102349A (en)	1999-02-26
WO1997029109A1 (fr)	1997-08-14
CN1205009A (zh)	1999-01-13
DE69736513D1 (de)	2006-09-28
NO981357L (no)	1998-08-03
PL327284A1 (en)	1998-12-07
NO310292B1 (no)	2001-06-18
NO981357D0 (no)	1998-03-25
CN1090189C (zh)	2002-09-04
HUP9900575A3 (en)	2001-11-28
ES2168237T3 (es)	2007-04-01
PL191271B1 (pl)	2006-04-28

Legal Events

Date	Code	Title	Description
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2005-10-17	MM4A	Lapsed by not paying the annual fees	Effective date: 20050130

Publication	Publication Date	Title
EE200000168A (et)	2001-04-16	Karboksamidotiasoolderivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE9800028A (et)	1998-08-17	Iprotroopiumsoolad, neid sisaldavad ravimkompositsioonid ja nende kasutamine
EE04673B1 (et)	2006-08-15	Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
HUP9701169A3 (en)	1999-07-28	Cycloalkano-pyridine derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
EE200200138A (et)	2003-06-16	Kinolüülpropüülpiperidiini derivaadid, nende valmistamine ja neid sisaldavad kompositsioonid
HUP0002272A3 (en)	2002-03-28	Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use
SI0918059T1 (en)	2003-12-31	Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them
HUP9801900A3 (en)	2001-02-28	2-methoxybenzophenone derivatives, intermediates, preparation thereof and fungicide compositions containing them
HUP9901243A3 (en)	2001-11-28	Quinazoline derivatives, preparation and use thereof, pharmaceutical compositions containing these compounds
IL190216A0 (en)	2008-11-03	Novel substituted imidazole compounds, their preparation and pharmaceutical compositions comprising them
EE200200065A (et)	2003-04-15	3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon
EE200300046A (et)	2004-10-15	Asabitsüklilised ühendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
IL112384A0 (en)	1995-03-30	Tetracyclic derivatives, their preparation and pharmaceutical compositions containing them
HUP0102102A3 (en)	2002-06-28	Pyrazoline derivatives, their preparation, pharmaceutical compositions containing them and their use
EE200000037A (et)	2000-10-16	Atsüülpiperasinüülpürimidiinide derivaadid, nende valmistamine ja kasutamine ravimitena
EE04276B1 (et)	2004-04-15	Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
ATE240315T1 (de)	2003-05-15	Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
HUP9904694A3 (en)	2001-12-28	Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them
EE9900015A (et)	1999-08-16	Sünteetilised polüsahhariidid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid
IL122740A0 (en)	1998-08-16	16-hydroxy-11-(substituted phenyl)-estra-9, 4-diene derivatives their preparation and pharmaceutical compositions containing them
HUP0101960A3 (en)	2003-03-28	Metabolites of ecteinascidin 743, their use and pharmaceutical compositions containing them
IL112443A0 (en)	1995-03-30	Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
FI951967A7 (fi)	1995-10-27	Uudet kaksirenkaiset aromaattiset yhdisteet, niitä sisältävät farmaseuttiset ja kosmeettiset koostumukset ja niiden käyttö
HUP9802132A3 (en)	2000-04-28	Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them
EE04348B1 (et)	2004-08-16	Sahhariidderivaadid, neid sisaldav farmatseutiline kompositsioon ja nende kasutamine